2,947 results match your criteria Future Oncology[Journal]


Illness acceptance as mediator for cancer-related complaints and psychological distresses among malaysian cancer patients.

Future Oncol 2019 Apr 18. Epub 2019 Apr 18.

Department of Radiology and Oncology, University Kebangsaan Malaysia Medical Centre, Hospital Canselor Tunku Muhriz, Wilayah Persekutuan Kuala Lumpur, Malaysia.

The present study investigated the relationship between psychological problems, illness acceptance and cancer-related complaints among Malaysian cancer patients. One-hundred and six cancer patients were recruited and were requested to complete validated self-reported questionnaires that measured their psychological distresses, sleep quality, pain, fatigue and illness acceptance. There was a significant relationship between cancer-related symptoms, illness acceptance and psychological distresses commonly experienced by local cancer patients (p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0686DOI Listing

Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence.

Future Oncol 2019 Apr 18. Epub 2019 Apr 18.

Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, PR China.

MTHFD1 was the enzyme providing one-carbon derivatives of tetrahydrofolate. We sought to investigate the impact of MTHFD1 on hepatocellular carcinoma (HCC). Bioinformatic analysis, western blot and immunohistochemistry were conducted to detect MTHFD1 expression in HCC. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0606
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0606DOI Listing
April 2019
1 Read

Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Radiation Oncology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY 10461, USA.

Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients.

Methods: Patients received chemoradiotherapy for locally advanced non-small-cell lung cancer and completed the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment before treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0874DOI Listing
April 2019
2 Reads

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Neuroncology Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53 00144, Rome, Italy.

Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG).

Patients & Methods:  The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months.

Results: We collected data of 197 RG patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0826DOI Listing

Exhaled breath biopsy: a new cancer detection paradigm.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler, Unit 1354, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0091DOI Listing
April 2019
1 Read

Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Bladder cancer (BC) is the most frequent cancer affecting the urinary tract. With the growing era of targeted therapies around the 2000s, many trials evaluated the efficacy of targeted therapy in advanced BC. However, no approval was given yet to any form of targeted therapy when it comes to BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0459DOI Listing
April 2019
1 Read

AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Immutep SAS; Parc Club Orsay, Orsay, France.

Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to induce sustained immune responses. Combining active immunotherapy with a standard cytotoxic chemotherapy regimen represents a promising novel strategy that might lead to therapeutic improvements in metastatic breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0807DOI Listing
April 2019
1 Read

E-cadherin germline mutations in Māori population.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Division of Breast Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0834DOI Listing
April 2019
3 Reads

Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology Nanjing University, Jiangsu, PR China.

Aim: To evaluate the prognostic values of some preoperative inflammation-based factors including C-reactive protein/albumin ratio (CRP/Alb) and platelet level in papillary renal cell carcinoma (PRCC).

Materials & Methods: A total of 108 PRCC patients underwent partial or radical nephrectomy were retrospectively analyzed. The prognostic values were determined with Kaplan-Meier analysis, univariate and multivariate COX regression models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0611DOI Listing
April 2019
1 Read

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Medical Oncology, National Cancer Center, 11 Hospital Drive, Singapore, 169690, Singapore.

The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC significantly improved progression-free survival and showed a clinically meaningful effect on overall survival in patients with PD-L1-positive tumors. The placebo-controlled randomized Phase III IMpassion132 (NCT03371017) trial is evaluating atezolizumab with first-line chemotherapy (capecitabine [mandatory in platinum-pretreated patients] or gemcitabine/carboplatin) for inoperable locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2019-0059
Publisher Site
http://dx.doi.org/10.2217/fon-2019-0059DOI Listing
April 2019
3 Reads

The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Future Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Currently, there are no predictive markers of response to abiraterone. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and at 4 and 12 weeks after initiation of abiraterone, and we evaluated prostate-specific antigen (PSA) response every 4 weeks in 102 metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone either pre- or postchemotherapy. With a median follow-up was 24. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0635DOI Listing

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Future Oncol 2019 Apr 10. Epub 2019 Apr 10.

Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0097DOI Listing

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Future Oncol 2019 Apr 10. Epub 2019 Apr 10.

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0951DOI Listing
April 2019
3 Reads

Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience.

Future Oncol 2019 Apr 10. Epub 2019 Apr 10.

Department of Medical Statistics & Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.

Aim: The present study aimed to determine whether anatomical resection was necessary for early hepatocellular carcinoma.

Methods: A log-rank test or two-stage test was used for univariate analysis. A Cox proportional hazards model was used for multivariable analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0117DOI Listing

Retrospective comparison of stereotactic body radiotherapy versus intensity-modulated radiotherapy for stage III ultra-central squamous non-small-cell lung cancer.

Future Oncol 2019 Apr 5. Epub 2019 Apr 5.

Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Road, Fengtai District, Beijing 100071, People's Republic of China.

Aim: To analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) versus intensity-modulated radiotherapy (IMRT) in stage III patients with ultra-central squamous non-small-cell lung cancer (sqNSCLC).

Methods: Forty-four stage III patients with ultra-central sqNSCLC receiving SBRT (n = 15) or IMRT (n = 29) between December 2014 and August 2017 were reviewed.

Results: At a median follow-up of 16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0061DOI Listing
April 2019
4 Reads

mirRNA-365b promotes hepatocellular carcinoma cell migration and invasion by downregulating SGTB.

Future Oncol 2019 Apr 3. Epub 2019 Apr 3.

Department of Obstetrics & Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, PR China.

Aim: miR-365b, a miRNA at chromosomal breakpoint, was often amplified and upregulated in human hepatocellular carcinoma (HCC). However, the role of miR-365b dysregulation remains unclear.

Materials & Methods: miR-365b function assays and its target gene analyses were performed. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0676
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0676DOI Listing
April 2019
4 Reads

Toward a better understanding of the mechanism of action for intra-arterial delivery of irinotecan from DC Bead (DEBIRI).

Future Oncol 2019 Apr 3. Epub 2019 Apr 3.

Biocompatibles UK Ltd, Lakeview, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK.

DC Bead is designed for the embolization of liver malignancies combined with local sustained chemotherapy delivery. It was first demonstrated around a decade ago that irinotecan could be loaded into DC Bead and used in a transarterially directed procedure to treat colorectal liver metastases, commonly referred to as drug-eluting bead with irinotecan (DEBIRI). Despite numerous reports of its safe and effective use in treating colorectal liver metastases patients, there remains a perceived fundamental paradox as to how this treatment works. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0071DOI Listing
April 2019
2 Reads
2.477 Impact Factor

Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.

Future Oncol 2019 Apr 3. Epub 2019 Apr 3.

Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC).

Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016.

Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0654DOI Listing
April 2019
2 Reads

Pertuzumab in HER2-positive early breast cancer: current use and perspectives.

Future Oncol 2019 Apr 2. Epub 2019 Apr 2.

Institut Jules Bordet - Université Libre de Bruxelles (U.L.B); Medical Oncology Department, Academic Promoting Team at Boulevard de Waterloo, 121, 1000, Brussels, Belgium.

Although the prognosis of HER2-positive breast cancer patients has dramatically improved with modern chemotherapy and the monoclonal antibody trastuzumab, up to 31% of them will experience a recurrence in the long term. After the unprecedented benefit in overall survival with the addition of the second monoclonal antibody pertuzumab for patients with metastatic disease, the drug was tested with various degrees of success in the preoperative and postoperative settings. In this review, we will focus on the pharmacologic aspects of the drug, including mechanism of action and toxicities, and discuss clinical data regarding its use in advanced and early stage HER2-positive breast cancer, placing in perspective the pros and cons regarding other available drugs and biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0896DOI Listing
April 2019
1 Read

High KCNQ1OT1 expression might independently predict shorter survival of colon adenocarcinoma.

Future Oncol 2019 Apr 1;15(10):1085-1095. Epub 2019 Apr 1.

Department of Gastrointestinal Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to School of Medicine, UESTC, Chengdu, 610041, PR China.

Aim: To explore the expression profile of KCNQ1OT1 and its prognostic value in colon and rectal adenocarcinoma (COAD and READ) separately.

Patients & Methods: clinicopathological, genomic and survival data from The Cancer Genome Atlas and GSE39582 were obtained for a secondary analysis.

Results: KCNQ1OT1 was significantly up-regulated in both COAD and READ compared with adjacent normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0499DOI Listing
April 2019
4 Reads

Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival.

Future Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China.

Aim: To study the expression of EIF5A2 in urinary tract urothelial carcinoma and its clinicopathological features and prognosis.

Methods: EIF5A2 expression was detected via immunohistochemistry in 101 patients.

Results: Kaplan-Meier analysis showed that the EIF5A2 low expression group had significantly longer overall survival (OS; p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0748DOI Listing
April 2019
1 Read
2.477 Impact Factor

Surgical management of multiple ipsilateral breast cancers.

Future Oncol 2019 Apr 29;15(11):1185-1191. Epub 2019 Mar 29.

Department of Surgery, Kyoto University Hospital, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0028DOI Listing
April 2019
2.477 Impact Factor

GPX3 hypermethylation in gastric cancer and its prognostic value in patients aged over 60.

Future Oncol 2019 Apr 29;15(11):1279-1289. Epub 2019 Mar 29.

Medical Genetics Center, Department of Genetics, School of Medicine, Ningbo University, Ningbo, Zhejiang, PR China.

Aim: This study investigated the association between GPX3 methylation and gastric cancer (GC), and explored its prognostic value in patients undergoing radical gastrectomy.

Materials & Methods: The methylation levels of tumor and paracancerous tissues were detected by quantitative methylation-specific PCR method.

Results: GPX3 was hypermethylated in GC (p = 4E-4), and was specific for patients with lymphatic metastasis (+), tumor invasion depth >3 cm and patients with poor differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0674DOI Listing
April 2019
1 Read

Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

Future Oncol 2019 Mar 28. Epub 2019 Mar 28.

Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, No. 87, Dingjiaqiao Road, Nanjing, 210009, China.

Aim: The clinical implications of PIK3CA mutations in gastric cancer (GC) are not conclusive.

Materials & Methods: A systematic searching of the previous publications and related studies in The Cancer Genome Atlas (TCGA) database were performed to investigate the clinical implications of PIK3CA mutations in GC.  Results: Twenty-six independent cohort studies including six studies with original data were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0335DOI Listing
March 2019
4 Reads

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia.

Future Oncol 2019 Mar 26. Epub 2019 Mar 26.

Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.

Aim: We used Adelphi Real World Disease-Specific Programme data to characterize adults with newly diagnosed or relapsed/refractory de novo acute myeloid leukemia (AML).

Materials & Methods: Community-practice hematologists/oncologists completed patient record forms for their regular AML patients. Patients were invited to complete patient self-completion forms including 3-Level EuroQol 5-Dimensions (EQ-5D-3L) and Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaires. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0842DOI Listing
March 2019
2 Reads

Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.

Authors:
Kelly E McCann

Future Oncol 2019 Mar 26. Epub 2019 Mar 26.

Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA.

Poly-ADP-ribosyl polymerase (PARP) enzymes PARP-1 and PARP-2 recognize DNA damage and set off a cascade of cellular mechanisms required for multiple types of DNA damage repair. PARP inhibitors are small molecule mimetics of nicotinamide which bind to PARP's catalytic domain to inhibit poly-ADP-ribosylation (PARylation) of target proteins, including PARP-1 itself. PARP inhibitors olaparib, veliparib, talazoparib, niraparib and rucaparib have predominantly been studied in women with breast or ovarian cancers associated with deleterious germline mutations in BRCA1 and BRCA2 (gBRCA1/2+). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0751DOI Listing
March 2019
1 Read

Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis.

Future Oncol 2019 Mar 22. Epub 2019 Mar 22.

Department of Breast Surgery, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, No.1630 Dongfang Road, Shanghai 200127, PR China.

Aim: Benefit of longer course of taxane-anthracycline-based adjuvant chemotherapy is yet to be identified.

Patients & Methods: We conducted a retrospectively matched-pair analysis to compare four cycles of fluorouracil, epirubicin and cyclophosphamide followed by four cycles of docetaxel (4FEC-4T) with three cycles of FEC followed by three cycles of docetaxel (3FEC-3T) as adjuvant chemotherapy for early-stage breast cancer. One hundred and thirty-seven patients treated with 4FEC-4T were matched to 411 in 3FEC-3T. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0666
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0666DOI Listing
March 2019
1 Read

Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.

Future Oncol 2019 Mar 20. Epub 2019 Mar 20.

Columbia University Irving Medical Center, NY, USA.

Eribulin is a novel microtubule inhibitor with mitotic and nonmitotic mechanisms of action. Both pooled and subgroup analyses from large-scale Phase III clinical trials demonstrated that eribulin has substantial activity in patients with pretreated (anthracycline and a taxane) advanced or metastatic breast cancer. We review recent pharmacological and clinical findings pertaining to eribulin use in metastatic breast cancer - particularly highlighting eribulin in difficult-to-treat and aggressive disease, and safety data in specific patient populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0936DOI Listing

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.

Future Oncol 2019 Mar 19. Epub 2019 Mar 19.

Boehringer Ingelheim International GmbH, Ingelheim, Germany.

Aim: Evaluate duration of therapy among patients treated with afatinib or erlotinib as first-line therapy for non-small-cell lung cancer (NSCLC).

Materials & Methods: NSCLC patients initiating afatinib or erlotinib between 2014 and 2017 were identified in three large claims databases in the USA. Propensity score matching was conducted to compare the duration of treatment between patients by treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0052DOI Listing
March 2019
1 Read
2.477 Impact Factor

A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions.

Future Oncol 2019 Mar 19. Epub 2019 Mar 19.

Phil Rivers Technology, Beijing 10095, PR China.

Aim: Utilize breast cancer samples in the same patient to indicate breast cancer development.

Patients & Methods: We performed whole-exome analysis of spatially independent ductal carcinoma in situ (DCIS) and invasive ductal carcinoma samples from the same breast.

Results: In VEGF pathway, we observed two genes disrupted in DCIS, while another four (including ACTN2) mutated in invasive ductal carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0555DOI Listing
March 2019
1 Read
2.477 Impact Factor

Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type?

Future Oncol 2019 Mar 19. Epub 2019 Mar 19.

Division of Oncogynecology, N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg 197758, Russia.

Aim: To compare endocrine characteristics of  endometrial cancer (EC) patients based on recent molecular EC types classification.

Materials & Methods:  A total of 234 treatment-naive EC patients as well their tumors were studied.

Results: Patients with POLE mutations demonstrated tendency to lower body mass index (BMI) and higher serum estradiol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0687DOI Listing

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.

Future Oncol 2019 04 19;15(10):1115-1123. Epub 2019 Mar 19.

Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

Aim: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

Patients & Methods: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once-daily oral mCTX treatment at a fixed dose of 50 mg.

Results: The treatment was well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0715DOI Listing

Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting.

Future Oncol 2019 Apr 19;15(11):1269-1277. Epub 2019 Mar 19.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Aim: To assess whether clinical trial participation affects survival outcomes of radiotherapy-treated localized prostate cancer patients compared with similar treatment within a real-world setting.

Methods: This is a comparative analysis of the outcomes of localized prostate cancer patients treated within two clinical trials (NCT00331773; NCT00004054) versus the outcomes of similar cohorts of patients registered within the SEER database and treated with radiotherapy. Propensity score matching was conducted to account for heterogeneity in background patient information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0539DOI Listing
April 2019
5 Reads
2.477 Impact Factor

Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine.

Future Oncol 2019 Apr 18;15(10):1125-1134. Epub 2019 Mar 18.

Department of Medicine & Surgery, Unit of Radiologic Science, University of Parma, Maggiore Hospital, Via Gramsci 14, Parma, Italy.

Computed tomography-guided lung biopsy is a valid and safe procedure for characterizing pulmonary nodules. In the past years, this technique has been mainly used to confirm the malignant nature of undetermined pulmonary lesions; however, today its role has been completely renewed. With the advent of target therapy and immunotherapy, it has arisen for lung cancer, in inoperable patients, the necessity to obtain adequate bioptical material to perform a correct molecular characterization of the lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0527DOI Listing

Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.

Future Oncol 2019 Mar 18. Epub 2019 Mar 18.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0850DOI Listing
March 2019
1 Read

The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights.

Future Oncol 2019 Mar 18. Epub 2019 Mar 18.

Department of Hematology, Fujian Provincial Key Laboratory of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, PR China.

Despite the progress made in molecular and clinical research, patients with diffuse large B-cell lymphoma (DLBCL) still have a bad prognosis. Recently, chemokines/chemokine receptors have become the subject of interest in relation to DLBCL. Studies have demonstrated the important role of chemokines/chemokine receptors in the communication between DLBCL cells and tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0514DOI Listing
March 2019
1 Read

Role of physical activity in onset, prevention and treatment of human neoplasms.

Future Oncol 2019 Apr 18;15(11):1181-1183. Epub 2019 Mar 18.

San Raffaele University, Via di Val Cannuta 247, Rome, 00166 Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0963DOI Listing

Breast cancer over-diagnosis: an adverse consequence of mammography screening - highlights of the 2018 Kyoto Breast Cancer Consensus Conference.

Future Oncol 2019 Apr 18;15(11):1193-1196. Epub 2019 Mar 18.

Kyoto University Hospital, Kyoto University Graduate School of Medicine, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0027DOI Listing
April 2019
2.477 Impact Factor

Young-onset rectal cancer patients: in need of answers.

Future Oncol 2019 Apr 18;15(10):1053-1055. Epub 2019 Mar 18.

Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0002DOI Listing

Understanding patient-reported outcome measures in colorectal cancer.

Future Oncol 2019 Apr 18;15(10):1135-1146. Epub 2019 Mar 18.

Department of Surgery, Western Health, The University of Melbourne, Melbourne, Victoria, Australia.

Quality of life has become increasingly regarded as a key outcome measurement for cancer patients. Patient-reported outcome measures (PROMs) represent the tools used to ascertain self-reported quality of life. This review provides a summary of the literature regarding the use of PROMs in colorectal cancer and evaluates the advantages and limitations of generic and disease specific questionnaires that can be utilized in clinical practice. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0723
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0723DOI Listing
April 2019
5 Reads

Tumor-induced mortality in adult primary supratentorial glioblastoma multiforme with different age subgroups.

Future Oncol 2019 Apr 18;15(10):1105-1114. Epub 2019 Mar 18.

Tianjin Cerebral Vascular & Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Department of Neurosurgery, Tianjin Huan Hu Hospital, Tianjin 300350, PR China.

Aim: To assess the independent determinants of tumor-induced mortality in different age subgroups after considering competing risk (CR).

Methods: Data were extracted from the SEER database. The independent determinants of tumor-induced mortality were defined by CR analysis and validated by conditional inference trees. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0719DOI Listing
April 2019
1 Read

Aldoxorubicin in soft tissue sarcomas.

Future Oncol 2019 Mar 15. Epub 2019 Mar 15.

Sarcoma Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, United Kingdom & The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, United Kingdom.

Aldoxorubicin is a prodrug formulation of doxorubicin currently under investigation for the treatment of soft tissue sarcomas. Early studies have demonstrated a promising reduction in the cardiotoxicity of aldoxorubicin compared with equivalent doses of doxorubicin leading to an increase in the equivalent cumulative dose of aldoxorubicin. The current clinical and pharmacological data available for aldoxorubicin are extremely promising for its use in the treatment of advanced and metastatic soft tissue sarcomas compared with equivalent doses of doxorubicin although Phase III data are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0922DOI Listing
March 2019
3 Reads

The 21-gene recurrence score and effects of adjuvant radiotherapy after breast conserving surgery in early-stage breast cancer.

Future Oncol 2019 Mar 13. Epub 2019 Mar 13.

Department of Radiation Oncology, Cancer Hospital, the First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen 361003, PR China.

Aim: To investigate the associations with the 21-gene recurrence score (RS) and effect of adjuvant radiotherapy (RT) for early-stage breast cancer after breast conserving surgery.

Methods: We included 13,246 patients in the Surveillance, Epidemiology and End Results database.

Results: Patients with a higher RS were independently related to nonreceipt of RT (p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0967DOI Listing
March 2019
1 Read

Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.

Future Oncol 2019 Apr 12;15(10):1067-1084. Epub 2019 Mar 12.

Department of Hematology and Oncology, The West Clinic, Germantown, TN 38138, USA.

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0872DOI Listing
April 2019
1 Read

By downregulating PBX3, miR-526b suppresses the epithelial-mesenchymal transition process in cervical cancer cells.

Future Oncol 2019 Mar 12. Epub 2019 Mar 12.

Department of Gynecology, The First Hospital of Lanzhou University, Lanzhou, 730000, China.

Aim: Research on novel mutant genes may develop the treatment of cervical cancer (CC). The role of miRNA-526b in epithelial-mesenchymal transition (EMT) of CC was investigated.

Methods: The role and the molecular mechanism of miRNA-526b in CC and its effect on EMT were analyzed in clinical specimens and oncology experiments. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0575
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0575DOI Listing
March 2019
5 Reads

Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastic non-small-cell lung cancer.

Future Oncol 2019 Mar 11. Epub 2019 Mar 11.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan 250117, China.

Aim: To compare the efficacy and toxicity of local therapy plus chemotherapy versus chemotherapy in non-small-cell lung cancer (NSCLC) patients with oligometastases after surgery.

Patients & Methods: A total of 152 patients with oligometastases after surgery were enrolled. Data of patient survival, treatment response and toxicities were compared between the groups receiving local ablative therapy plus chemotherapy and chemotherapy alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0923DOI Listing

Corrigendum.

Authors:

Future Oncol 2019 Mar 11;15(9):1051. Epub 2019 Mar 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0098c1DOI Listing

Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

Future Oncol 2019 Mar 11;15(9):925-927. Epub 2019 Mar 11.

Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0503DOI Listing
March 2019
1 Read

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

Future Oncol 2019 Mar 11. Epub 2019 Mar 11.

Danish Center for Clinical Health Services Research, Aalborg University, Aalborg, Denmark.

Aim: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer management. Materials & methods: Real-world data source selection for I-O Optimise followed a structured approach focused on population coverage, key variable capture, continuous/consistent data availability, record duration and data latency, and database expertise. Results: As of 31 October 2018, seven real-world data sources were included in I-O Optimise, providing data on characteristics, treatment patterns and clinical outcomes from more than 45,000 patients/year with non-small-cell lung cancer, small-cell lung cancer and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0025DOI Listing
March 2019
3 Reads

Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.

Authors:
Cora N Sternberg

Future Oncol 2019 Mar 8. Epub 2019 Mar 8.

Division of Medical Oncology, Weill Cornell Medical Center, New York, NY 10021, USA.

Androgen receptor (AR) signaling is a key pathway in prostate cancer, and patients are initially treated with androgen deprivation therapy. Patients, who have stopped responding to androgen deprivation therapy, are considered to have castration-resistant prostate cancer (CRPC), which is still dependent on AR signaling. Enzalutamide, an orally available AR inhibitor, was initially approved by the US FDA for the treatment of patients with metastatic CRPC who have previously received docetaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0940DOI Listing